Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease. - Test2 - elhamkhani - TriplyDB

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.

http://www.wikidata.org/entity/Q36517542

about

Drug development in Alzheimer's disease: the path to 2025 Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico Effect of LXR/RXR agonism on brain and CSF Aβ40 levels in rats Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation.RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Aβ oligomers.Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease.Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases.Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models.Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer's Disease.Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics.Preclinical PET Neuroimaging of [11C]Bexarotene.A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects Remyelinating Pharmacotherapies in Multiple Sclerosis.Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease.Binding of Bexarotene to the Amyloid Precursor Protein Transmembrane Domain in Liposomes Alters its α-Helical Conformation but Inhibits γ-Secretase Non-Selectively.

P2860

Q27007748-7C2A4029-7E1A-4D9D-8C0C-373701354DB3 Q28551351-05D75F2B-5B22-4B78-937E-394824A80C70 Q28602802-B0C4BE03-BB18-4E3E-888C-83D9D5AAD1BF Q30239964-E1C92600-AAEC-48B7-81EE-198514E126AA Q36774123-09AD665E-4261-43DF-9E82-8FA8815AB537 Q37644290-0C73D694-FFE9-479D-92B5-A93CD3D85607 Q38407177-AF183AC5-0291-4261-9383-74EA5CA45617 Q38715276-C64BB955-A2F0-4C04-B7D6-3933D5970037 Q38891157-29949D00-0C20-4094-9192-CFE0CDF55072 Q39005365-642D4395-C328-4E40-909A-AA355BD08EF7 Q39164346-FA91BE82-6EC4-47EC-AF71-5E88BBEAAB9A Q39689655-6F58025B-30E1-435F-944E-8218DFDFCE65 Q41015702-5192CA37-D694-4276-8BAA-88F45D64B23B Q42689665-19649C27-C801-4776-BE0D-49358990D377 Q46682011-52427501-C4E0-4DF5-AC76-A3EBA6ECF438 Q47677964-5F9DC140-3DFF-413A-9ABF-827FFA516348 Q49962878-393313D4-AEE3-4714-922B-9A980FCDF22E Q52714855-8E0AD3D8-05DA-442A-BB1D-430E7754E808

P2860

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.

http://www.wikidata.org/entity/Q36517542

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Double-blind, placebo-controll ...... moderate Alzheimer's disease.

@ast

Double-blind, placebo-controll ...... moderate Alzheimer's disease.

@en

type

label

Double-blind, placebo-controll ...... moderate Alzheimer's disease.

@ast

Double-blind, placebo-controll ...... moderate Alzheimer's disease.

@en

prefLabel

Double-blind, placebo-controll ...... moderate Alzheimer's disease.

@ast

Double-blind, placebo-controll ...... moderate Alzheimer's disease.

@en

P1433

Q36517542-C9AE5BD9-D1C3-409A-A0B1-E7834468829E

P1476

Q36517542-C39F0785-2522-4467-8E4E-3D6BA8910FFC

P2093

Q36517542-273705C5-9EA8-4862-B7DD-94B775497B5C

Q36517542-441DC06A-AF61-4646-A3EE-204251D98A69

Q36517542-58EF85C9-B6CB-4847-89AC-062D0E1BBDB9

Q36517542-67A66030-E0D9-49A8-B3E7-9FC43B3035E3

Q36517542-6AFD9C98-C1AE-4BF8-86F9-A12D94373AD9

Q36517542-93F8F247-14DB-4167-BE6A-E11423833CB0

Q36517542-9549D6EC-AF70-4C28-86DB-3A42643313E6

Q36517542-AAC7E8B5-5B15-45C9-90E9-BB941F76C18A

Q36517542-B5DFF616-2329-4F7C-9658-86A3C953B236

P2860

Q36517542-00946E60-CC26-4F5D-983B-42FDB7EBB19F

Q36517542-048592BB-951F-43B5-9F43-395D9F413CBB

Q36517542-092FE5D2-2270-41B4-82B2-FA3B9C6C26E3

Q36517542-0A090BB0-B2AA-4C97-B2B1-395DA84F0C2F

Q36517542-0EE48F65-2357-49F6-B4F2-48F050834B99

Q36517542-11764A76-C52D-4875-BFFB-AC82D5AD4745

Q36517542-175F2020-F2EE-459D-BA29-32B7CCA015CD

Q36517542-23EE2E79-3FE9-4119-BC0A-F64F9F2660F4

Q36517542-24FFBDF7-006C-49E0-BC33-78A1CBA1F893

Q36517542-259A40A8-B747-4E64-9140-E5457066F7C2

P2888

Q36517542-5AE5CB26-21F6-472A-A151-71F9AF7817A6

P304

Q36517542-0A5803D9-6636-4DEA-AFF4-7711D1C59BCC

P31

Q36517542-C51DEFD0-DB1D-424E-B220-6699DAEC0B4F

P356

Q36517542-87A0BCA5-0C42-4315-B1E9-E63BCF425B3A

P407

Q36517542-F5DBAD73-11DB-4297-9AC7-0B715D72B8AD

P478

Q36517542-95064389-C73B-4D02-BC77-CCDD984EA164

P50

Q36517542-FCC138B3-DE53-4471-9757-4106F5EB7232

P577

Q36517542-596FD036-6E09-41AF-AF48-DCA1D7F5B91B

P5875

Q36517542-8E60EC77-E7DB-431C-A652-D5D10E390832

P6179

Q36517542-B652DD43-9A1A-4C29-852E-374A160757DE

P698

Q36517542-0056E128-568D-4965-B1C4-19A20DF96C52

P921

Q36517542-92F559D6-385E-4CDF-BE2C-6AE13B38366F

Q36517542-C54FFF2A-5587-4162-B607-5E8A5A3D0F37

P932

Q36517542-B9CF410D-6E33-4E59-9B6D-0A1C7807C63B

P356

S13195-016-0173-2

P1433

Alzheimers Research & Therapy

P1476

Double-blind, placebo-controll ...... moderate Alzheimer's disease.

@en

P2093

Abhinay Joshi

http://www.w3.org/2001/XMLSchema#string

Anne Tang

http://www.w3.org/2001/XMLSchema#string

Chelcie Heaney

http://www.w3.org/2001/XMLSchema#string

James Bena

http://www.w3.org/2001/XMLSchema#string

Jefferson W Kinney

http://www.w3.org/2001/XMLSchema#string

Joanne Moll-Tudla

http://www.w3.org/2001/XMLSchema#string

Kate Zhong

http://www.w3.org/2001/XMLSchema#string

Michael Devous

http://www.w3.org/2001/XMLSchema#string

Michael Pontecorvo

http://www.w3.org/2001/XMLSchema#string

P2860

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

“Mini-mental state”

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways

Monetary costs of dementia in the United States

Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"

Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"

The Clinical Dementia Rating (CDR): current version and scoring rules

P2888

s13195-016-0173-2

P304

4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13195-016-0173-2

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey L. Cummings

P577

2016-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

292175817

http://www.w3.org/2001/XMLSchema#string

P6179

1039647768

http://www.w3.org/2001/XMLSchema#string

P698

26822146

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4731943

http://www.w3.org/2001/XMLSchema#string